Viable Mycobacterium avium subsp. paratuberculosis isolated from calf milk replacer


Published in:
Journal of Dairy Science

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
© 2017, The Authors. Published by FASS and Elsevier Inc. on behalf of the American Dairy Science Association®.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
ABSTRACT

When advising farmers on how to control Johne’s disease in an infected herd, one of the main recommendations is to avoid feeding waste milk to calves and instead feed calf milk replacer (CMR). This advice is based on the assumption that CMR is free of viable Mycobacterium avium ssp. paratuberculosis (MAP) cells, an assumption that has not previously been challenged. We tested commercial CMR products (n = 83) obtained from dairy farms around the United States by the peptide-mediated magnetic separation (PMS)-phage assay, PMS followed by liquid culture (PMS-culture), and direct IS900 quantitative PCR (qPCR). Conventional microbiological analyses for total mesophilic bacterial counts, coliforms, Salmonella, coagulase-negative staphylococci, streptococci, nonhemolytic Corynebacterium spp., and Bacillus spp. were also performed to assess the overall microbiological quality of the CMR. Twenty-six (31.3%) of the 83 CMR samples showed evidence of the presence of MAP. Seventeen (20.5%) tested positive for viable MAP by the PMS-phage assay, with plaque counts ranging from 6 to 1,212 pfu/50 mL of reconstituted CMR (average 248.5 pfu/50 mL). Twelve (14.5%) CMR samples tested positive for viable MAP by PMS-culture; isolates from all 12 of these samples were subsequently confirmed by whole-genome sequencing to be different cattle strains of MAP. Seven (8.4%) CMR samples tested positive for MAP DNA by IS900 qPCR. Four CMR samples tested positive by both PMS-based tests and 5 CMR samples tested positive by IS900 qPCR plus one or other of the PMS-based tests, but only one CMR sample tested positive by all 3 MAP detection tests applied. All conventional microbiology results were within current standards for whole milk powders. A significant association existed between higher total bacterial counts and presence of viable MAP indicated by either of the PMS-based assays. This represents the first published report of the isolation of viable MAP from CMR. Our findings raise concerns about the potential ability of MAP to survive manufacture of dried milk-based products.

Key words: Mycobacterium avium ssp. paratuberculosis, milk replacer, calf health, Johne’s disease, infectious disease control

INTRODUCTION

Milk replacer has been fed to calves since at least the 1950s, although formulations have changed over the years in terms of percentage of fat and protein. Calf milk replacers (CMR) are generally made with by-products originating from milk processing industries, such as whole milk powder, skim milk powder, casein, whey, and whey protein, although protein sources other than milk by-products such as soy products, dried egg, fish protein concentrates, and single cell protein may also be used (FAO, 2011; Bovine Alliance on Management and Nutrition, 2014). Most dairy calves in the United States are fed milk replacer before weaning for reasons of convenience, biosecurity, and economics (Costello, 2012; Bovine Alliance on Management and Nutrition, 2014). Calves are particularly susceptible to infectious diseases, and some infectious agents such as Mycobacterium avium ssp. paratuberculosis (MAP), the cause of Johne’s disease (JD), bovine viral diarrhea virus, bovine leukemia virus, Pasteurella multocida, Salmonella sp., and Mycoplasma bovis can be transmitted from cow to calf through feeding unpasteurized milk (Costello, 2012). Feeding CMR, as an alternative to feeding waste unpasteurized milk or farm-pasteurized milk, is a common practice in the United States. The latest statistics from the National Herd Monitoring Scheme indicate that 49.9% of all US dairy operations (of all sizes) fed
some kind of CMR to pre-weaned heifers during 2014; 16.4% of operations fed nonmedicated CMR and 37.6% fed medicated CMR (USDA, 2016).

As mentioned above, calves may be fed CMR to prevent diseases such as JD, caused by MAP, which is shed in the milk and feces of infected cows. Transmission of MAP is considered to be an early event in a calf’s life, and there are recognized risk factors for transmission of MAP to calves within dairy herds (Doré et al., 2012). A focus of JD control programs is calf-related interventions as part of herd management plans. Avoiding feeding waste milk and feeding CMR instead is a key recommendation within JD control programs worldwide (Doré et al., 2012; Garcia and Shalloo, 2015; Pieper et al., 2015). As stated by Cooper and Watson (2013), the assumption has always been that the risk of viable MAP organisms in commercial CMR powders is negligible because CMR is invariably pasteurized and often highly processed, but is that really the case? Seemingly, to date, no one has ever challenged that assumption.

Demonstrating the existence of viable MAP in processed milk or dairy products, such as pasteurized milk, cheeses, yogurt, milk powders, and powdered infant formula, has proven difficult because, until recently, culture always necessitated inclusion of a chemical decontamination step to inactivate non-MAP contaminants; the latter is known to adversely affect the viability of some or all of the MAP cells present in milk, potentially leading to negative culture results (Dundee et al., 2001; Gao et al., 2005). However, detection methods for viable MAP in milk and dairy products have improved considerably over recent years with the advent of immunomagnetic separation (Grant et al., 1998; O’Brien et al., 2016) and subsequently peptide-mediated magnetic separation (PMS; Stratmann et al., 2002, 2006; Foddai et al., 2010; O’Brien et al., 2016), which permit selective capture, separation, and concentration of whole MAP cells from a sample before culture or PCR, and novel mycobacteriophage-based methods of MAP detection (Stanley et al., 2007; Foddai et al., 2010; Swift et al., 2013; Botsaris et al., 2016), which require the MAP cells to be viable to obtain a positive result (plaques in a lawn of fast-growing Mycobacterium smegmatis). In particular, a method combining PMS and a phage amplification assay to detect MAP (PMS-phage assay), developed and optimized by Foddai et al. (2009, 2011), and used in combination with an optimized milk sample preparation protocol (Foddai and Grant, 2015), is proving to be a very sensitive method of detecting viable MAP in cow milk. The optimized PMS-phage assay was recently reported to have a limit of detection 50% of ~1 MAP cell per 50 mL of milk, making it a more sensitive detection method than existing quantitative PCR for MAP and conventional culture methods (Foddai and Grant, 2017).

As time passes and the novel optimized PMS-phage assay is applied to test various milk and dairy products, new information on the presence and numbers of viable MAP in these foods is emerging (Foddai and Grant, 2017). We previously reported the outcome of testing of powdered infant milk formula (PIF) by the PMS-phage assay (Grant et al., 2014). Of 68 PIF samples tested, 30 (44.1%) samples tested positive for viable MAP by the PMS-phage assay, with viable MAP numbers ranging from 4 to 678 pfu/50 mL of reconstituted PIF indicated by the plaque counts obtained. Because PIF and CMR are similar milk-based, powdered dairy products, probably with not dissimilar production processes, our viable MAP in PIF findings led us to query whether testing of CMR by the PMS-phage assay might also yield similar results with respect to the presence of viable MAP. Preliminary testing of a small number of CMR samples sourced in Wisconsin by the PMS-phage assay (carried out before the CMR testing reported here) found that 1 (12.5%) of 8 CMR samples tested positive for viable MAP. We hypothesized that viable MAP may be more widely prevalent in commercial powdered CMR products, so we decided to carry out a larger study. The objectives of the study were (1) to test commercial CMR products sourced from within the United States using standard culture methods, 2 PMS-based methods (PMS-phage assay and PMS plus liquid culture) and IS900 quantitative PCR (qPCR) to detect the presence of viable MAP and MAP DNA, respectively, and (2) to assess the overall hygienic quality of the CMR samples by performing conventional microbiological analyses, to determine if the presence of any hygiene indicator microorganism might correlate with detection of viable MAP. An optimized method for detecting MAP in powdered dairy products has yet to be published, so during this study multiple methods, including several published and unpublished cultural and qPCR approaches (detailed below), were employed in the 2 CMR testing laboratories to maximize chances of detecting low numbers of viable MAP, if present, in the CMR samples.

MATERIALS AND METHODS

Acquisition of CMR Samples

The CMR samples were acquired in 2 stages. In the first stage, 50 samples were acquired during the summer of 2014 from dairy farms in southern Wisconsin by author Tarrant. Hygiene precautions were taken to avoid on-farm contamination. Samples were col-
lected with a sterile plastic scoop into sterile transport bags, with a separate sterile scoop being used for each sample. If a sealed bag of CMR was available on the farm, that bag was used for sampling; the majority of the 50 Wisconsin-sourced CMR samples were obtained from unopened bags of CMR (James Tarrant, University of Wisconsin–Madison, personal communication). Subsequently, during the spring of 2015, an additional 35 CMR samples were acquired from across the United States. For CMR collection outside Wisconsin, sample collection kits, including sterile scoops and bags, were mailed to veterinarians and veterinary students with detailed instructions about hygienic sampling technique and a request to use a sealed CMR bag if possible; all except 2 of the 35 CMR samples obtained in other US states were recorded as being from unopened bags. The 83 CMR samples ultimately tested originated from 15 US states and included 35 different brands of CMR representing 6 unique manufacturers.

**CMR Sample Reconstitution**

Unless otherwise stated, 6 to 9 g of each CMR sample (as indicated by the manufacturer’s label) was aseptically weighed into a sterile 50-mL centrifuge tube, reconstituted to 50 mL with pre-warmed (37°C) sterile distilled water, shaken thoroughly for several minutes to ensure resuspension of all powder, and then placed at 4°C overnight to fully rehydrate. Next day, the reconstituted CMR samples were removed from the fridge and allowed to equilibrate to room temperature for at least 1 h before being centrifuged at 3,000 × g for 15 min at room temperature. Each CMR pellet was then resuspended in 1 to 5 mL of PBS (pH 7.4) containing 0.05% Tween 20 (PBS-T), as appropriate depending on the size of pellet obtained, to obtain what was considered to be a suitable consistency for PMS. The volume of PBS-T added was recorded so that a correction factor could be applied to plaque counts obtained when 1 mL of each CMR pellet sample was subjected to the PMS-phage assay. Finally, the reconstituted CMR pellet samples were ultrasonicated (pulse mode 37 kHz for 4 min in ice water) in an Ultrasonic bath (FB-11201, Fisher Scientific Ltd., Loughborough, UK) to break up any MAP clumps in the sample before PMS was performed. Only one sample of each CMR was tested by each of the methods described below, so intra- or inter-laboratory variation for the methods employed was not evaluated during this study.

**PMS of MAP from Reconstituted CMR**

The PMS was performed on 1 mL of each sample (prepared as indicated above) using 5 µL of biotinylated-aMptD aMptD peptide-coated MyOne Tosylactivated Dynabeads (Life Technologies, Paisley, Scotland, UK), prepared in-house as previously described (Foddai et al., 2010). A positive (1 mL of a 10⁻¹ dilution of a broth culture of MAP B2) and negative (1 mL of 7H9 broth) control sample was included with each batch of 15 to 20 CMR samples processed. Magnetic separation was carried out using a Dynal BeadRetriever (Life Technologies). The MAP cell capture was carried out for 30 min at room temperature under continuous mixing, followed by 2 washes in 1 mL of PBS-T, and final resuspension of the beads in 1 mL of Middlebrook 7H9 broth containing 10% (vol/vol) OADC supplement (7H9/OADC broth) and NOA antibiotic supplement (Abtek Biologicals Ltd., Liverpool, UK; final concentrations per liter: 50,000 IU of nystatin, 2 mg of oxacillin, and 30 mg of aztreonam). This final 1-mL bead sample was split equally between the phage assay and culture, carried out as described below. The positive and negative PMS controls were also processed through the phage assay (PMS-phage assay) and culture (PMS-culture) along with each batch of test samples.

**PMS-Phage Assay**

The PMS-phage assay and confirmatory plaque-PCR were carried out as follows: after PMS, 500 µL of each bead sample was transferred to a 11-mL flip-top vial (Capitol Vials, Auburn, AL) containing 500 µL of 7H9/OADC/4 mM CaCl₂/NOA antibiotics (final CaCl₂ concentration in sample, 2 mM) before being incubated overnight at 37°C. The phage assay was carried out as described by Foddai et al. (2009). Briefly, 100 µL of D29 mycobacteriophage suspension (10⁹ pfu/mL) was added to each bead sample, before incubation for 2 h at 37°C. Then, to inactivate exogenous/nonadsorbed seed phage, 100 µL of freshly prepared 100 mM ferrous ammonium sulfate (Sigma-Aldrich, Poole, Dorset, UK) was added to each sample and allowed to incubate for 10 min at room temperature, with thorough vortexing of the sample after 5 min, before the addition of 5 mL of 7H9/OADC/2 mM CaCl₂/NOA broth. Samples were returned to the incubator at 37°C for a further 90 min before being plated with tempered (55°C) Middlebrook 7H9 agar containing 10% OADC (both Difco) and 1 mL Mycobacterium smegmatis mc² 155 (10⁸ cfu/mL). Plaques were counted following overnight incubation of plates at 37°C. Plaque counts obtained were expressed as plaque-forming units per 50 mL of reconstituted CMR; direct plaque counts were multiplied by a factor of 2 to take account of the fact that only half of the bead sample (equivalent of 25 mL of reconstituted CMR) was processed through the phage assay, and by
a factor of 1, 3, or 5 to take account of the differing volumes of PBS-T originally added to resuspend the CMR pellets.

Plaque-IS900 PCR, essentially as described by Swift et al. (2013), was carried out on DNA extracted from plaques to confirm that the DNA present was MAP DNA and not from some other *Mycobacterium* sp. Up to a maximum of 10 plaques were randomly selected from each PMS-phage assay positive sample plate to be excised for DNA extraction. The center of each plaque was excised using a sterile loop and transferred to an Eppendorf tube. The DNA was extracted from the plaques using the Zymoclean Gel DNA Recovery kit (Cambridge Bioscience Ltd., Cambridge, UK), according to the manufacturer’s instructions. The DNA was eluted from the Zymoclean columns using 20 µL of elution buffer (supplied with kit). The DNA was stored at −20°C until required for plaque-PCR. A protocol modified from Whittington et al. (1998) was used to target the IS900 insertion element. To 40 µL of master mix containing 1 × DreamTaq Green Buffer, 2.5 mM MgCl2, 200 µM of each dNTP, 1 U Fermentas DreamTaq DNA polymerase (Thermo Fisher Scientific, UK), and 250 ng of P90 5′ GAAAGGTGTTCGGGGC-GTCCGCTTAGG 3′ and P91 5′ GGCGTTGAGGTC-GATCGCCC ACGTGAC 3′ primers, 10 µL of plaque DNA was added. The PCR cycling conditions were 94°C for 5 min, 37 cycles of 94°C for 30 s, 62°C for 30 s and 72°C for 1 min, final extension at 72°C for 4 min, and then the sample was cooled to 4°C. The PCR products were visualized by 2% agarose gel electrophoresis. The expected IS900 PCR product size was 400 bp.

**PMS Culture at Queen’s University Belfast**

The PMS-culture and confirmation of suspected positive cultures was carried out as follows: 500 µL of each bead suspension after PMS was inoculated into screw-capped glass test tubes containing 5 mL of modified Middlebrook 7H9 liquid medium (Pozzato et al., 2011), consisting of (per 900 mL) 4.7 g of Middlebrook 7H9 powder, 1.0 g of casitone, 5 mL of glycerol supplemented with 10% vol/vol OADC supplement and PANTA plus antibiotic supplement (all Becton Dickinson and mycobactin J (2 mg/L; Symbiotics Europe SAS, Lyon, France), but without the addition of 16% egg yolk. The broth cultures were incubated at 37°C and absorbance at optical density at 600 nm (OD$_{600nm}$) was measured at time 0 and then from 4 wk onward every 2 wk up to 16 wk using a Biowave CO8000 Density meter (Biochrom Ltd., Cambridge, UK). When an increase in OD$_{600nm}$ was observed, at which point IS900 PCR was applied to confirm presence of MAP cells. Any primary PMS-culture suspected of containing viable MAP was sub-cultured to Dubos broth medium, prepared as described by Hammer et al. (2002) including the addition of 20% Newborn Calf Serum (Life Technologies), PACT antibiotics (50 IU/mL of polymyxin B, 5 µg/mL of amphotericin B, 25 µg/mL of carbenicillin, and 2.5 µg/mL of trimethoprim, all Sigma) and mycobactin J (2 mg/L, Symbiotics Europe SAS), and onto Herrold’s egg yolk medium (HEYM) containing 2 mg/L of mycobactin J (prepared in-house). Once again, OD$_{600nm}$ of broth cultures was measured periodically until an increase was observed, at which point IS900 PCR was applied to confirm the presence of MAP DNA. IS900 PCR was also applied to suspect colonies growing on HEYM plates to confirm their identity.

**PMS Culture at University of Wisconsin–Madison**

Reconstituted CMR was processed by PMS using the KingFisher Duo Prime Purification System (Thermo-Fisher Scientific, Fitchburg, WI) to concentrate MAP and then inoculated into MGIT ParaTB medium with 1.0 mL of MGIT ParaTB supplement (which contains mycobactin J), 500 µL of egg yolk emulsion and 200 µL of MGIT PANTA added, and also onto HEY slants (all culture media and supplements from BD Diagnostic Systems, Sparks, MD). For one set of MGIT ParaTB medium cultures, the CMR was reconstituted as previously described (as per manufacturer label instructions; 6–9 g/mL). For the other cultures, all CMR samples were reconstituted at a standard 5 g/50 mL and allowed to rehydrate before testing commenced. If suspicious colonies were seen on HEY or if the MGIT 960 instrument was signal-positive, a 5-target multiplex PCR was performed to establish if MAP was present (Shin et al., 2010). The nature of the CMR material inoculated onto solid media tended to resemble bacterial growth, causing many cultures to be unnecessarily tested. In total 149 cultures (including both PMS cultures and conventional cultures) were tested by multiplex PCR.

**Conventional Culture for MAP at University of Wisconsin–Madison**

The sample processing method described by Botsaris et al. (2016) in a study of powdered infant formula was adapted and used with 3 different culture media. The CMR was first reconstituted in PBS pH 7.2 at 1.0 g/5 mL, allowed to sit at 20°C for 1 h, centrifuged at 2,500 × g for 15 min at room temperature. The pellet was resuspended in 0.75% hexadecylpyridinium chloride (HPC) and allowed to sit for 4 h at 20°C. After cen-

Journal of Dairy Science Vol. 100 No. 12, 2017
trifugation at 2,500 × g for 15 min at room temperature the pellet was resuspended in 1.0 mL of sterile water. Three media were inoculated: 200 µL onto HEY slants (BD Diagnostic Systems); 100 µL into MGIT ParaTB medium (BD Diagnostic Systems) supplemented with mycobactin J, egg yolk, and PANTA; and 100 µL onto modified 7H10 agar plates supplemented with mycobactin-J, ADC, and VAN. Suspicious colonies on solid culture media (HEY or 7H10) and signal-positive MGIT cultures were tested by multiplex PCR, as described above for PMS-cultures, to establish if MAP had been isolated. The nature of the CMR material inoculated onto solid media tended to resemble bacterial growth causing many cultures to be unnecessarily tested.

**IS900 qPCR at University of Wisconsin–Madison**

Three method variations were used to test CMR samples for presence of MAP by IS900 qPCR.

**Method 1.** For the first qPCR method, the CMR was reconstituted at 5 g/50 mL in sterile water, then held at 4°C for 18 to 24 h before centrifugation at 2,500 × g for 15 min. The pellet was resuspended in 3.0 mL of sterile PBS containing 0.05% Tween 20. The DNA was extracted from 1.0 mL of this suspension using the Tetracore Extraction System (Tetracore, Rockville, MD) using the 1.0-g protocol after agitation in the Benchmark BeadBlaster 24 (Benchmark Scientific, Inc., Edison, NJ). From the 25-µL extraction product, 5 µL was used as template DNA for IS900 qPCR.

**Method 2.** For the second qPCR method, CMR was first reconstituted in PBS at 1.0 g/5 mL, allowed to sit at 20°C for 1 h, centrifuged at 2,500 × g for 15 min. The pellet was resuspended in 0.75% HPC and allowed to sit for 4 h at 20°C. After centrifugation at 2,500 × g for 15 min the pellet was resuspended in 1.0 mL of sterile water. The DNA was extracted from this suspension using the Tetracore Extraction System (Tetracore) using the 1.0-g protocol after agitation in the Benchmark BeadBlaster 24 (Benchmark Scientific). From the 25-µL extraction product, 5 µL was used as template DNA for IS900 qPCR.

**Method 3.** For the third qPCR method, the CMR was reconstituted at 1.0 g/9 mL, then held at 20°C for 1 h, then overnight at 4°C for 18 to 24 h. After centrifugation at 2,500 × g for 15 min, the pellet was reconstituted in 1.0 mL of sterile Tris-EDTA buffer pH 8.0. The DNA was extracted from this suspension using the Tetracore Extraction System (Tetracore) using the 1.0-g protocol after agitation in the Benchmark BeadBlaster 24 (Benchmark Scientific). From the 25-µL extraction product, 5 µL was used as template DNA for IS900 qPCR.

**Conventional Microbiological Analyses at University of Wisconsin–Madison**

All CMR samples were reconstituted as per manufacturer label instructions: 6 to 9 g/50 mL. The resulting milk sample was then tested by the same methods used to characterize the microbiological quality of bulk tank milk. Freshly reconstituted CMR was tested at the following 4 final dilutions: 1:50, 1:500, 1:5,000, and 1:50,000. Heat-stressed reconstituted milk replacer (37°C for 6 h) was tested at the same dilutions with the addition of 2 higher dilutions to anticipate the higher microbial counts: 1:100,000 and 1:500,000. Final dilutions were achieved by inoculating 0.2 mL of each primary dilution onto Trypticase soy agar (BAP) supplemented with 5% sheep blood (Remel Inc., Lenexa, KS) for determination of microorganism growth and total bacterial counts and eosin methylene blue agar (Remel Inc.) to quantify lactose fermenters (coliforms) and noncoliform, gram-negative bacteria. Culture plates were incubated at 36°C in 5% CO2 and examined for growth after 24, 48, and 36 h of incubation. Each dilution was also inoculated onto XLT4 agar (Remel Inc.), incubated in ambient air at 35°C and examined for growth of *Salmonella* after 24, 48, and 36 h of incubation. In addition, enrichment culture for *Salmonella* was performed to increase sensitivity of *Salmonella* detection. Undiluted reconstituted CMR (0.2 mL) was inoculated into selenite and Rappaport-Vassiliadis enrichment broths (Remel Inc.). Enrichment broths were incubated for 18 h in ambient air at 35°C and then subcultured onto XLT4 agar (Remel Inc.). Subcultures were incubated in ambient air at 35°C and examined for colonies resembling *Salmonella* after 24 and 48 h of incubation. Colony counts were recorded on the last day of incubation. All colony types were identified and classified into the following groups: coliform or noncoliform, gram-negative rods (lactose positive or negative on eosin methylene blue, respectively), streptococci (*agalactiae* or non-*agalactiae*), staphylococci (*Staph. aureus* or CNS), *Corynebacterium* spp., *Bacillus* spp., or other microorganism using standard microbiological procedures (Hogan et al., 1999). Other microorganisms or species level identifications were performed by MALDI-TOF MS (Bruker Daltonics, Bremen, Germany).

**Genomic Analysis of MAP Isolates**

When MAP isolates were successfully cultured at Queen’s University Belfast (QUB), genomic DNA was extracted from cells grown in Dubos broth according to a method supplied by Adel Talaat, University of Wisconsin–Madison.
Wisconsin–Madison (Hsu et al., 2011). Briefly, this involved heating at 80°C for 20 min to kill the mycobacterial cells, lysozyme, and proteinase K treatments to weaken the cell wall, and addition of 5 M NaCl and cetrimonium bromide/NaCl to lyse the MAP cells. This was followed by (1) phenol/chloroform/isoamyl alcohol (24:24:1) extraction, (2) chloroform/isoamyl alcohol (24:1) extraction, (3) precipitation of DNA with isopropanol overnight, (4) washing with 70% ethanol, and (5) resuspension of DNA pellet in 30 µL of sterile molecular grade water. The purity and yield of DNA from each suspect MAP isolate was provisionally checked using a Biophotometer (Eppendorf, Hamburg, Germany) before the DNA samples were sent to the DNA Sequencing Facility, University of Wisconsin Biotechnology Center (Madison, WI). All DNA samples were sequenced using Illumina Miseq platform and were run in paired-end with 250 bp for each read. Raw sequencing files were imported to CLCBio Genomic workbench version 8 for reference assembly using MAP K10 (NC_002944). Single nucleotide polymorphisms, multiple nucleotide variant, and whole genome insertions/deletions were also analyzed using CLCBio software. The criteria for variant calling included that a variant has ≥20 times sequence coverage where this variant is present in ≥50% of the sequence reads. The consensus sequence of each sample was then extracted from CLCBio software and used to build a phylogenetic tree using HarvestTools (Treangen et al., 2014). Finally, to distinguish MAP genotypes (type I vs. II or III), hsp65, gyrA, and gyrB PCR followed by enzyme digestion were performed as detailed previously by Castellanos et al. (2007) and Ghosh et al. (2012).

Statistical Analysis

The microbiological quality of CMR was compared for CMR samples that tested positive for viable MAP by phage assay or culture and those that did not, using the Mann-Whitney test with GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA); a difference with \( P \)-value ≤ 0.05 was considered significant at the 95% confidence level.

RESULTS

PMS-Phage Assay (QUB)

Thirty-three (39.8%) of the 83 CMR samples tested by the PMS-phage assay yielded plaques, in which the presence of MAP DNA was detected by plaque-PCR in 17 cases (Table 1); thus, the presence of viable MAP was confirmed in 17 (20.5%) of the 83 CMR samples tested. Viable MAP numbers, indicated by plaque numbers in confirmed PMS-phage assay positive samples, ranged from 6 to 1,212 pfu/50 mL of reconstituted CMR (mean 248.5 pfu/50 mL).

PMS Culture (QUB) or Conventional MAP Culture (University of Wisconsin–Madison)

At QUB, primary liquid cultures of 29 of the 83 CMR samples in modified Middlebrook 7H9 medium (Pozzato et al., 2011) without egg yolk demonstrated an increase in OD\(_{600}\) of 0.1 to 0.7 units within the 16-wk incubation period. When ZN stained, 18 of these cultures were observed to have acid-fast cells present, so they were deemed suspect positive cultures. When the 18 suspect positive primary broth cultures were subcultured to Dubos medium and HEYM, 12 continued to show evidence of growth (an increase in OD\(_{600}\)) in liquid culture or appearance of suspect colonies typical of MAP after 4 to 6 wk on HEYM. All 12 suspect cultures tested \( IS900 \) PCR so were provisionally identified as MAP. Ultimately, pure Dubos broth cultures of viable MAP were obtained from 12 (14.5%) of the 83 CMR samples originally tested. The DNA was subsequently extracted from these pure broth cultures and sent to University of Wisconsin–Madison (UW) for whole-genome sequencing.

At UW, CMR samples were cultured after PMS or conventional MAP culture protocols involving HPC decontamination in MGIT ParaTB medium supplemented with egg yolk. None of the UW cultures were positive for viable MAP.

\( IS900 \) qPCR for MAP (UW)

Seven (8.4%) of the 83 CMR samples were \( IS900 \) qPCR-positive with Ct values of 28.3 to 35.6, which translates to roughly 10 to 100 cfu of viable and non-viable MAP/g of CMR. Five of the 7 qPCR-positive samples (71%) were also positive by a test for viable MAP (PMS-phage assay or PMS-culture) at QUB (Figure 1).

Inter-Relationships Between Test Results

Table 1 provides details of the PMS-phage assay, PMS-culture, and qPCR results for 26 (31.3%) of the 83 CMR samples, which yielded a positive result by any of the 3 tests applied. Twenty-four (92.3%) of these CMR samples tested positive for the presence of viable MAP by either PMS-phage assay or PMS-culture, or both tests. The MAP isolates were successfully cultured from 12 CMR samples overall. Only one CMR sample (KY-12), originating from a dairy farm in Kentucky, tested positive for MAP by all 3 tests applied (Table 1).
**Limited and Whole-Genome Sequencing of Suspect MAP Isolates from CMR**

Limited genotyping using *hsp65*, *gyrA*, and *gyrB* indicated that the 12 suspected MAP isolates are from cattle source (type II) and do not belong to types I or III. These isolates were from 3 different US states, but the majority of isolates (n = 10/12) were from Wisconsin. We also performed whole-genome sequence analysis to further assay genomic diversity among isolates and begin to track the prevalence of MAP collected from CMR. The whole-genome sequence analysis confirmed that the 12 CMR isolates were MAP strains, as expected from the limited genotyping. In fact, more than 99% of the sequencing reads were mapped to reference cattle strain, MAP-K10 (Table 2). Identification of SNP among isolates and the standard laboratory strain (MAP-K10) revealed large numbers of SNP that ranged between 151 and 267 SNP per genome, most of which were shared among isolates from Wisconsin source CMR (Figure 2A). Interestingly, the percentages of nonsynonymous SNP were much higher than synonymous SNP, and only a few SNP were present in the intergenic regions (Figure 2B). As expected, a phylogenetic tree of SNP predicted from each genome (Figure 2C) showed a clear distinction from the MAP_S397 strain originally isolated from a sheep (Bannantine et al., 2012), but was closely related to the K10 isolate from a cow (Wynne et al., 2010). In addition, genomes from all CMR isolates clustered separately from genomes recently isolated from elk circulating in California (David Press, Wildlife Ecologist, Point Reyes National Seashore, Inverness, CA, personal communications). The sheer number of SNP and their cluster pattern, different from traditional bovine strains used in most Johne’s testing laboratories, suggests a common source for these MAP isolates from CMR collected in 4 different states.

### Table 1. Detailed peptide-mediated magnetic separation (PMS)-phage assay, PMS-culture, and direct IS900 quantitative PCR (qPCR) results, and US state of origin information, for the 26 calf milk replacer (CMR) samples that tested positive by one or more of the Mycobacterium avium ssp. paratuberculosis (MAP) detection tests

<table>
<thead>
<tr>
<th>CMR code (US state of origin-sequence no.)</th>
<th>No. of plaques per 50 mL of reconstituted CMR</th>
<th>Plaque IS900 PCR result</th>
<th>PMS-culture</th>
<th>Direct IS900 qPCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>WI-001</td>
<td>696</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>WI-002</td>
<td>822</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>WI-003</td>
<td>150</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>WI-004</td>
<td>38</td>
<td>+</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>WI-006</td>
<td>0</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>WI-007</td>
<td>0</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>WI-012</td>
<td>1,720</td>
<td>−</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>WI-013</td>
<td>1,212</td>
<td>+</td>
<td>(weak)</td>
<td>+</td>
</tr>
<tr>
<td>WI-014</td>
<td>0</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>WI-025</td>
<td>0</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>WI-038</td>
<td>30</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>WI-048</td>
<td>0</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>WI-050</td>
<td>80</td>
<td>+</td>
<td>(weak)</td>
<td>+</td>
</tr>
<tr>
<td>TX-004</td>
<td>12</td>
<td>0−</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>KY-006</td>
<td>12</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>UT-010</td>
<td>30</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>KY-012</td>
<td>40</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>OH-013</td>
<td>1,020</td>
<td>+</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>NY-015</td>
<td>6</td>
<td>+</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>KY-016</td>
<td>0</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>GA-017</td>
<td>10</td>
<td>+</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>KY-020</td>
<td>0</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>IA-026</td>
<td>6</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>NY-027</td>
<td>6</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>WA-031</td>
<td>30</td>
<td>+</td>
<td>(weak)</td>
<td>+</td>
</tr>
<tr>
<td>NY-032</td>
<td>36</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Total no. of positive CMR samples</td>
<td></td>
<td></td>
<td></td>
<td>17</td>
</tr>
<tr>
<td>Average no. of MAP (pfu/50 mL of reconstituted CMR) in test positive samples³</td>
<td>248.5</td>
<td>116.7</td>
<td>153.7</td>
<td></td>
</tr>
</tbody>
</table>

¹Only CMR sample known to have been collected from an already opened bag of CMR.

²All 12 isolates from culture-positive CMR samples were subjected to whole-genome sequencing with the results shown in Figure 2.

³The average number of pfu/50 mL of reconstituted CMR for PMS-culture and qPCR positive samples were calculated based on the number of pfu indicated by the corresponding PMS-phage assay result for those samples; a negative PMS-phage assay result equated to 0 pfu/50 mL of reconstituted CMR.
Standard measures of microbiological quality of CMR are summarized in Table 3. Total bacterial counts for the reconstituted 83 CMR samples ranged from 0 to 5.65 log_{10} cfu/mL of reconstituted CMR (mean 2.66 ± 1.28 log_{10} cfu/mL). Bacillus spp. represented the largest proportion (61%) of bacteria in most CMR (mean 2.33 ± 1.23 log_{10} cfu/mL), followed by Streptococcus spp. (not agalactiae, 18%, mean 1.01 ± 1.44 log_{10} cfu/mL) and CNS spp. (4%, mean 0.27 ± 0.91 log_{10} cfu/mL; Table 3). However, most striking was the large variation in microbiological quality among CMR samples tested. Eight samples had no bacterial growth detected at all. One CMR had a log_{10} total count of 3.18 per mL after reconstitution, all of which was due to Streptococcus spp. Another CMR sample had a log_{10} total count of 5.2 per mL after reconstitution, all of which was due to Bacillus spp. No Salmonella spp. were detected in any CMR sampled, even after heat stressing the reconstituted CMR and using enrichment culture for Salmonella. Furthermore, no Streptococcus agalactiae or coagulase-positive Staphylococcus aureus were detected in any of the tested CMR.

When comparing microbiological results for viable MAP-positive CMR (PMS-phage assay or PMS-culture positive) to MAP-negative CMR, only total plate counts were significantly higher for MAP-positive CMR ($P = 0.024$; Mann-Whitney test).

**DISCUSSION**

To our knowledge, this is only the second report of testing of commercial CMR products for the presence of viable MAP. The first CMR study (Khol et al., 2017) reported negative results for 18 commercial CMR samples obtained from 15 different CMR manufacturers tested by qPCR and culture preceded by chemical decontamination. In the present study, 3 MAP detection approaches were taken (culture/PMS-culture, PMS-phage assay, and IS900 qPCR) and viable MAP was detected in 24 (26%) of the 83 commercial CMR products tested, by either the PMS-phage assay or PMS-culture, or by both tests. As this CMR testing was not as a result of randomized sampling this figure may not reflect the true viable MAP contamination rate for CMR more generally. Also, the CMR were collected on-farm, rather than directly from CMR manu-

![Figure 1](image-url)

**Figure 1.** Venn diagram showing the interrelationships between results obtained by the peptide-mediated magnetic separation (PMS)-phage assay, PMS-culture, and direct IS900 quantitative PCR (qPCR) for 83 calf milk replacer (CMR) samples. Overlapping areas indicate numbers of CMR samples positive by more than one of the Mycobacterium avium ssp. paratuberculosis detection tests.

**Table 2.** Reference assembly summaries for 12 Mycobacterium avium ssp. paratuberculosis (MAP) isolates cultured from calf milk replacer (CMR) during this study, and for 4 unrelated elk MAP isolates

<table>
<thead>
<tr>
<th>MAP isolate no.</th>
<th>Total reads</th>
<th>% Mapped reads</th>
<th>Average coverage</th>
<th>No. of SNP</th>
</tr>
</thead>
<tbody>
<tr>
<td>WI-004</td>
<td>2,596,628</td>
<td>99.35</td>
<td>125.66</td>
<td>204</td>
</tr>
<tr>
<td>WI-006</td>
<td>2,632,574</td>
<td>99.44</td>
<td>127.26</td>
<td>251</td>
</tr>
<tr>
<td>WI-007</td>
<td>3,050,230</td>
<td>99.39</td>
<td>139.58</td>
<td>201</td>
</tr>
<tr>
<td>WI-012</td>
<td>2,617,894</td>
<td>99.57</td>
<td>127.73</td>
<td>213</td>
</tr>
<tr>
<td>WI-013</td>
<td>2,990,666</td>
<td>96.31</td>
<td>148.78</td>
<td>256</td>
</tr>
<tr>
<td>WI-014</td>
<td>2,407,414</td>
<td>99.28</td>
<td>123.36</td>
<td>259</td>
</tr>
<tr>
<td>WI-025</td>
<td>2,535,896</td>
<td>99.42</td>
<td>130.18</td>
<td>256</td>
</tr>
<tr>
<td>WI-048</td>
<td>2,288,424</td>
<td>99.47</td>
<td>117.59</td>
<td>256</td>
</tr>
<tr>
<td>WI-050</td>
<td>2,612,622</td>
<td>99.04</td>
<td>133.55</td>
<td>257</td>
</tr>
<tr>
<td>KY-012</td>
<td>2,966,602</td>
<td>99.41</td>
<td>152.25</td>
<td>257</td>
</tr>
<tr>
<td>KY-016</td>
<td>2,504,488</td>
<td>98.87</td>
<td>132.39</td>
<td>257</td>
</tr>
<tr>
<td>WA-031</td>
<td>2,439,940</td>
<td>99.2</td>
<td>127.79</td>
<td>252</td>
</tr>
<tr>
<td>Elk8B-1</td>
<td>2,121,874</td>
<td>99.38</td>
<td>100.83</td>
<td>142</td>
</tr>
<tr>
<td>Elk8B-2</td>
<td>2,683,464</td>
<td>99.41</td>
<td>130.28</td>
<td>150</td>
</tr>
<tr>
<td>Elk10A</td>
<td>2,628,938</td>
<td>99.61</td>
<td>128.71</td>
<td>146</td>
</tr>
<tr>
<td>Elk10B</td>
<td>2,746,440</td>
<td>99.59</td>
<td>134.07</td>
<td>148</td>
</tr>
</tbody>
</table>

1 The first 2 letters of MAP isolate no. relate to the US state where the CMR sample was collected.
facturers, so the possibility of cross-contamination of some samples with MAP on potentially MAP-infected farms cannot completely be ruled out. Numbers of viable MAP indicated by the plaque-PCR confirmed PMS-phage assay results ranged from 6 to 1,212 pfu/50 mL of reconstituted CMR (mean 248.5 pfu/50 mL). Plaques harvested from 16 of the 33 CMR samples yielding plaques were not confirmed to contain MAP DNA by plaque-PCR; this may reflect insensitivity of the PCR when low levels of MAP DNA are present (e.g., DNA from a single MAP cell per plaque rather than a clump of MAP cells per plaque) and hence false-

**Table 3.** Results of microbiological analyses performed on the 83 calf milk replacer (CMR) products that were tested for the presence of viable *Mycobacterium avium* ssp. *paratuberculosis* (MAP) to elucidate numbers and types of bacteria present.

<table>
<thead>
<tr>
<th>Item</th>
<th>Total plate count</th>
<th>Gram-negative bacteria</th>
<th>Gram-positive bacteria²</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Coliforms</td>
<td>Noncoliforms</td>
</tr>
<tr>
<td>Minimum count</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Maximum count</td>
<td>5.65</td>
<td>2.19</td>
<td>2.74</td>
</tr>
<tr>
<td>Mean count</td>
<td>2.66</td>
<td>0.03</td>
<td>0.03</td>
</tr>
<tr>
<td>SD</td>
<td>1.28</td>
<td>0.24</td>
<td>0.30</td>
</tr>
</tbody>
</table>

¹Data presented are minimum, maximum, and mean counts (log₁₀ cfu/mL) obtained for each analysis following reconstitution of the CMR samples according to manufacturer’s instructions in sterile water.

²Strep = *Streptococcus* spp.; Coryne = *Corynebacterium* spp.; Bac = *Bacillus* spp.
negative plaque-PCR results may have been obtained. However, the more likely explanation is that the virucide step did not achieve complete inactivation of the D29 phages added to the PMS sample at the start of the phage assay, so some plaques observed were due to residual D29 phages and not mycobacterial cells bursting to release progeny D29 phages. This latter scenario is the main reason why the confirmatory plaque-PCR step must be included. The MAP DNA was directly detected in just 7 CMR samples by IS900 qPCR, 5 of which also tested PMS-culture or PMS-phage assay positive. It is unknown whether the mean number of viable MAP indicated by the PMS-phage assay for the MAP culture-positive CMR samples (248.5 pfu/50 mL of reconstituted CMR), would represent sufficient inoculum to infect a calf, but the cumulative MAP dose from birth to weaning would not be insignificant, given the volume of CMR consumed by a calf over this period.

Suspected viable MAP isolates were cultured from 12 different CMR samples overall by liquid culture, with no chemical decontamination applied before culture. From the outset of the study, we were very cognizant that the suggestion may be made that laboratory cross-contamination could have contributed to any MAP positive cultures obtained, so the following practical measures were taken to avoid cross-contamination with viable MAP within the laboratory at QUB: (1) CMR samples were weighed out and/or reconstituted in a laboratory where MAP had never been worked with, and not in the CL2 laboratory where viable MAP may have been present; (2) sterile, single-use disposable plasticware was routinely used for all manipulations and transfers in the CL2 laboratory; (3) brand new screw-cap glass culture tubes were used for the CMR PMS-cultures and Dubos sub-cultures, and not recycled glassware that may have been previously used to culture MAP; and (4) CMR cultures were not opened until there was evidence of an increase in OD<sub>600nm</sub> at which point a ZN stain was carried out to check for presence of acid-fast cells. If acid-fast positive, the culture was aseptically sub-cultured into Dubos liquid medium (without egg yolk), Herrold’s egg yolk medium to stimulate more copious growth of MAP. It is difficult to explain the discrepant culture results at UW and QUB; we can only speculate on possible reasons. There were several distinct differences in terms of CMR sample preparation and culture media employed. First, at QUB, once the CMR pellet was resuspended, the samples were subjected to an ultrasonication treatment to break up clumps of MAP cells. This may have had the effect of releasing viable or sub-lethally injured MAP cells from among predominantly dead cells (particularly after heat treatment) in clumps, giving them (greater) access to nutrients during primary culture in Pozzato medium. Second, no egg yolk was added to either the primary (Pozzato modified Middlebrook medium) or secondary (Dubos broth) culture media at QUB, whereas UW adds egg yolk routinely to liquid MGIT medium. The purpose of adding egg yolk to culture media used for MAP is still unclear, but neutralization of the chemical decontaminant HPC seems to be a common reason (Whittington 2010). Whittington et al. (2013) subsequently suggested that egg yolk provides major carbon and energy sources as well as the surfactant lecithin. The question arises, are sub-lethally injured MAP cells likely to benefit from, or be adversely affected by, such a rich source of nutrients when trying to repair heat or dessication damage? Third, the primary culture medium adopted by QUB contained added casitone (0.1%, 1 g/L) and a higher than normal amount of Culture of CMR was carried out using several different published methods. Conventional culture methods normally used for bovine fecal samples at UW or the method used to detect MAP in powdered infant formula by Botsaris et al. (2016), in the hands of very experienced technicians in UW, failed to recover any viable MAP; these methods involved chemical decontamination before culture, which was similar to the approach taken by Khol et al. (2017) in their recent CMR study. Only a milk sample preparation and culture approach, optimized over recent years by researchers at QUB, was successful in isolating viable MAP from 12 CMR samples during this study. This approach included (1) allowing time (overnight at 4°C following reconstitution of CMR) for complete rehydration of MAP cells present in CMR before testing commenced, (2) PMS to selectively capture MAP cells from CMR rather than exposing potentially injured MAP cells to a chemical decontamination treatment, (3) primary culture for up to 16 weeks in a modified Middlebrook 7H9 liquid medium (first described by Pozzato et al., 2011), which had casitone added but no egg yolk, to permit resuscitation of sub-lethally injured MAP cells, and (4) sub-culture of any primary cultures once evidence of MAP growth was observed into richer Dubos liquid medium (without egg yolk) and Herrold’s egg yolk medium to stimulate
glycerol (0.5%, as per the Pozzato et al. (2011) recipe, rather than 0.2%, which is the amount indicated by the manufacturer (Difco) of Middlebrook 7H9 broth). The additional ingredient, casitone, is a pancreatic enzymatic digest of casein (milk protein) that contains a particularly high content of AA and peptides of varying sizes, making it a nutritious hydrolysate (BD Biosciences, 2017). Glycerol, or alternatively Tween 80, both of which are surfactants, can be added to Middlebrook 7H9 broth to reduce clumping of mycobacterial cells during culture, although, as stated above, 0.2% is the recommended glycerol concentration for this purpose. Glycerol would also represent a carbon source; a very old publication (Sattler and Youmans, 1948) relating to the effects of glycerol on tubercle bacilli (M. tuberculosis) reported that glucose and glycerol increased their total amount of growth but not their initial rate of multiplication. In light of the MAP isolation success at QUB during this study, we would like to suggest that the optimal culture approach for isolation of MAP from powdered milk products could be liquid culture in the modified 7H9 medium of Pozzato et al. (2011), with PANTA but without egg yolk, following PMS to capture MAP cells from reconstituted CMR that has had time to completely rehydrate before testing commences. Chemical decontamination with HPC should definitely be avoided because of its known deleterious effects on the viability of MAP cells (Dundee et al., 2001, Gao et al., 2005), and therefore, the distinct possibility that false-negative results will be obtained when testing dairy products containing low numbers of MAP. The latter, plus the fact that solid Herrold’s egg yolk medium rather than a liquid culture medium was used by Khol et al. (2017), could explain their negative culture findings for CMR. Liquid culture is likely to be more conducive to recovery of stressed MAP cells than culture on solid agar medium simply because the bacterial cells are able to access water and nutrients more readily.

When CMR samples were being sourced for this study, every effort was made to hygienically collect CMR on the farms visited and to collect CMR samples from unopened bags. The vast majority of the 26 CMR samples that tested MAP positive (Table 1) were sampled from unopened bags; just one of the positive samples (OH-013) is known to be from an already opened bag of CMR. However, the possibility of contamination of CMR samples by manure on the farm during collection cannot be totally ruled out because of the difficulties in maintaining hygienic practices in a dirty sampling environment, despite the best efforts of sampling personnel involved. Generally, all of the conventional measures of microbiological quality applied to the CMR samples were within normal limits for whole milk powders as set down in USDA-Agricultural Marketing Service Standards for milk and dairy products. These standards stipulate total bacterial counts <500,000 cfu/g and coliform counts ≤10 cfu/g for dry whole milk powders (USDA-AMS, 2001). The only statistically significant association between the conventional microbiological analyses and viable MAP presence in CMR was in relation to total plate counts, which were found to be significantly higher for viable MAP-positive CMR than for MAP-negative CMR (P = 0.024; Mann-Whitney test). In our opinion, this association does not necessarily indicate greater contamination of the CMR with MAP on-farm, but rather could reflect the possibility that the raw milk used to produce CMR ingredients contained higher numbers of MAP that have been able to survive heat treatments applied during milk powder production.

**CONCLUSIONS**

Viable MAP were detected in 24 (28.9%) of 83 CMR samples collected at US dairy farms; 12 were positive by PMS-culture, 17 by PMS-phage assay, and 5 samples were positive by both of these tests. A further 2 CMR samples tested positive for MAP DNA by IS900 qPCR. The presence of viable MAP in CMR was significantly associated with higher total bacterial counts, but with none of the other microbiological parameters. This is the first report of viable MAP in CMR, but not the first report of viable MAP in powdered milk products. The source of the viable MAP detected cannot be verified, whether pre- or postprocessing contamination. It is unknown if the quantity of MAP detected in CMR would be sufficient to cause infection of a calf. However, the prospect that MAP has survived the manufacture of dried milk and whey-based products, which are destined for consumption by food animals could have far-reaching potential consequences; further testing of CMR collected directly at manufacturing sites using the PMS and liquid culture approach described above is warranted to verify our findings. The broader food safety implications of detecting viable MAP in this type of dried dairy product are not insignificant given that powdered infant formulae is consumed by young babies with immature immune systems.

**ACKNOWLEDGMENTS**

Funding for this study was obtained from the Wisconsin Agriculture Experiment Station (Madison; award number MSN169060), the American Association of Bovine Practitioners (Ashland, OH), and the Walter and Martha Renk Endowed Laboratory for Food Safety (Madison, WI). James Tarrant’s involvement in
the study was funded by the Merial-National Institutes of Health Summer Scholars Program (Duluth, GA). Whole-genome sequencing of the suspect MAP isolates obtained from CMR was partially supported by grant NIFA 2013-67015 from the USDA (Washington, DC) to Adel Talaat.

REFERENCES


